India Outlines Plan to Boost Inspections of Drug Facilities - Pharmalot - WSJ:
"Last year, the FDA conducted 111 inspections in India, up from 98 in 2011 and 59 in 2009, and has issued warning letters to several Indian drug makers. Significantly, the FDA also issued 21 so-called import alerts that allow the FDA to ban products from entering the U.S.
One widely known example is Ranbaxy Laboratories [500359.BY +1.16%], which is prevented from sending products from four of its plants in India and is also operating under a consent decree that requires improvements before the ban can be lifted. Sun Pharmaceuticals [524715.BY +1.46%] recently agreed to buy Ranbaxy for $3.2 billion"
'via Blog this'
Return Home: The Health, Drug, Prescription, and GMP Supersite Blog
SkillsPlus Intl Inc. - The best GMP training, best QSR training, best instructors
cGMP Mini-Series - Short Videos for GMP Trainer Use
SkillsPlus Intl Info Blog
The Designated Rep and Exemptee Professionals Blog
The Health, Drug, Prescription, and GMP Supersite Gift Store
Shaming Children So Parents Will Pay the School Lunch Bill
38 minutes ago